RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on DexCom (NASDAQ:DXCM) but lowers the price target from $165 to $145.
July 26, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on DexCom but lowers the price target from $165 to $145.
The Outperform rating suggests continued confidence in DexCom's performance, but the lowered price target indicates some caution about future growth. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100